Clinical trial exposes deadly kidney cancer's Achilles' heel
(UT Southwestern Medical Center) An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2020 Category: Cancer & Oncology Source Type: news

' Incredible' Results With Kidney Cancer Agent With Nobel Ties'Incredible' Results With Kidney Cancer Agent With Nobel Ties
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Novel targeted drug shows promise in advanced kidney cancer
(Dana-Farber Cancer Institute) Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC
Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

SIR highlights use of percutaneous ablation for RCC
Some patients with renal cell carcinoma (RCC) can be effectively treated nonsurgically...Read more on AuntMinnie.comRelated Reading: SIR aims for more awareness of interventional radiology SIR taps Findeiss as new president SIR: Virtual reality beats fluoroscopy for catheter placement SIR: 'OK, Google -- scrub up!' SIR: Stroke treatment training program improves outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2020 Category: Radiology Source Type: news

Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery
The risk of recurrence in surgically treated renal-cell carcinoma (RCC) persists beyond five years after surgery, suggesting the need for continued surveillance, according to a new analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2019 Category: Consumer Health News Tags: Urology News Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression - free survival longer in those receiving tivozanib as third - or fourth - line therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 23, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
MONDAY, Dec. 23, 2019 -- Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy, according to a study published online Dec. 3 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2019 Category: Pharmaceuticals Source Type: news

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma
On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck& Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study: Mesothelioma Patients with CD70 Protein Have Worse Prognosis
An international team of pathologists has identified a new protein often found on pleural mesothelioma tumor cells. The discovery could lead to a more accurate prognosis for patients and future treatment advances. Researchers found for the first time that mesothelioma patients expressing higher levels of the CD70 protein typically experience a much shorter survival, regardless of cell type or treatment type. “These markers might be useful for MPM [malignant pleural mesothelioma] prognostic evaluations, as well as targeted therapeutics,” the study authors wrote. “Further analyses in syngeneic mouse models...
Source: Asbestos and Mesothelioma News - December 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart
(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news

Renal Cancer Research by Sengenics and the University of Leeds Awarded...
This collaboration will focus on discovery of novel biomarkers for renal cell carcinoma (RCC), with the goal of developing an autoantibody-based early diagnostic test for this disease(PRWeb November 26, 2019)Read the full story at https://www.prweb.com/releases/renal_cancer_research_by_sengenics_and_the_university_of_leeds_awarded_early_detection_primer_grant_funding_from_cancer_research_uk/prweb16740467.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 26, 2019 Category: Pharmaceuticals Source Type: news

Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2019-- AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 4, 2019 Category: Drugs & Pharmacology Source Type: news

Renal Cell Carcinoma: 5 Things to Know Renal Cell Carcinoma: 5 Things to Know
What you need to know about the latest data on treating this common cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Pediatric Renal Cell Carcinoma Pediatric Renal Cell Carcinoma
What knowledge have we gained regarding the presentation and management of renal cell carcinoma in young patients?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, and causes the accumulation of hypoxia-inducible factor 2α (HIF-2α). HIF-2α inhibitors are effective in some ccRCC cases, but both de novo and acquired resistance have been observed in the laboratory and in the clinic. Here, we identified synthetic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inactivation in two species (human and Drosophila) and across diverse human ccRCC cell lines in culture and xe...
Source: Signal Transduction Knowledge Environment - October 1, 2019 Category: Science Authors: Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Kaelin, W. G. Tags: STKE Research Articles Source Type: news

Assessing costs of sunitinib treatment in renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

Aveo CEO says new data eases concerns about troubled kidney cancer drug
Cambridge drugmaker Aveo Oncology is trying again with its kidney cancer drug tivozanib, disclosing new late-stage data Tuesday that sent its stock price shooting up more than 40 percent and adding $60 million to the troubled company ’s market cap.  Tivozanib was developed to treat advanced renal cell carcinoma, the most common form of kidney cancer. But Aveo has been keeping tivozanib on life support since the FDA rejected it back in 2013 due to a higher risk of death or toxicity than the industry’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 10, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

A Lesson in Screening For Hereditary Kidney Cancer Syndromes A Lesson in Screening For Hereditary Kidney Cancer Syndromes
This case of a renal cell carcinoma in a 30-year-old highlights the need for screening for hereditary kidney cancer syndromes in patients diagnosed with RCC at a young age.Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2019 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Setbacks and Advances in Renal Cell Carcinoma Treatment Setbacks and Advances in Renal Cell Carcinoma Treatment
Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Favorable five-year survival reported for patients with advanced cancer treated with the immunotherapy
(Johns Hopkins Medicine) A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2019 Category: International Medicine & Public Health Source Type: news

Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients
A new study looked at targeted vs nontargeted therapy in real world patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney Cancer
Nivolumab had limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma, according to recent trial results. (Source: CancerNetwork)
Source: CancerNetwork - July 8, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Pembrolizumab/axitinib too costly in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2019 Category: Drugs & Pharmacology Source Type: news

Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer
Targeted therapies were associated with"modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study Reveals Lower Predictive Ability for Renal Cancer Models
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology. Andres... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2019 Category: Pharmaceuticals Source Type: news

Many elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
(University of Pennsylvania School of Medicine) Many elderly patients with metastatic renal cell carcinoma (RCC) -- who are often underrepresented in clinical trials to treat the kidney cancer -- are seeing overall survival benefits from treatment with targeted therapies, according to a new study published in JAMA Network Open. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 20, 2019 Category: International Medicine & Public Health Source Type: news

Do Brain Metastases Rule Out Immunotherapy in RCC?
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Dr. Daniel George on the Treatment Landscape for RCC
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Daniel George, MD Source Type: news

Patient Outcomes for Atezolizumab vs Sunitinib in Renal Cell Carcinoma
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving  atezolizumab alone or in combination with bevacizumab vs sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Carmena Trial: Should Nephrectomy Be Standard for Metastatic RCC?
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs  sunitinib alone in patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Benefit of Pembrolizumab/Axitinib Combo in Intermediate/Poor-Risk RCC
Pembrolizumab plus axitinib significantly improved overall survival, progression-free survival, and response rate as first-line treatment compared with sunitinib in patients with metastatic renal cell carcinoma (RCC) with intermediate/poor risk disease and those with sarcomatoid features, according to results of the KEYNOTE-426 study (abstract 4500) presented at the 2019 American Society of Clinical Oncology (ASCO) (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Pazopanib Followed by Nivolumab Shows Real-World Benefit in Metastatic RCC
The study  of sequential treatment of pazopanib followed by nivolumab in advanced or metastatic renal cell carcinoma looked at benefit-risk profile and survival. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Advanced Refractory RCC: TIVO-3 Results Presented for Tivozanib vs Sorafenib
Progression-free survival was compared for the VEGF TKI tivozanib vs  sorafenib across multiple subgroups of refractory advanced renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Effect of Pazopanib on Survival After Metastasectomy in Metastatic RCC
The study investigators evaluated the survival benefit of  pazopanib in metastatic renal cell carcinoma patients with no evidence of disease after metastasectomy. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Safety of Immune Checkpoint Inhibitors With Nephrectomy in mRCC
A pilot study evaluated  cytoreductive surgery combined with immune checkpoint therapy in patients with metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
(ECOG-ACRIN Cancer Research Group) The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, show no disease-free survival benefit with the use of one year of pazopanib in patients with metastatic renal cell carcinoma (kidney cancer) who had no evidence of disease following surgery to remove further metastases. There was a trend toward decreased overall survival with pazopanib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news

Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer
The anti-VEGF monoclonal antibody bevacizumab combined with the anti-PD-L1 antibody atezolizumab might beat sunitinib in some patients with previously untreated advanced renal-cell carcinoma (RCC), but uncertainty remains, according to a phase 3 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 30, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Merck acquires Peloton Therapeutics for $1 billion
The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 21, 2019 Category: Pharmaceuticals Source Type: news

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2019 Category: International Medicine & Public Health Source Type: news

Avelumab & #43; Axitinib Approved for Treatment of Renal Cell Carcinoma
THURSDAY, May 16, 2019 -- Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced. The agency based the approval on data... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news

FDA approves avelumab plus axitinib for renal cell carcinoma
On May 14, 2019, the Food and Drug Administration approved avelumab (BAVENCIO ®, EMD Serono, Inc.) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals
The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

FDA Okays Another Immunotherapy Plus TKI for Advanced RCC FDA Okays Another Immunotherapy Plus TKI for Advanced RCC
The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 15, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA
Approval marks the first anti-PD-L1 therapy combination for RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019– Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2019 Category: Drugs & Pharmacology Source Type: news